The Rise of the Perimenopause Telehealth Boom

The landscape of women's midlife health is shifting toward a hyper-niche telehealth model. As Wired first reported, a combination of regulatory changes, the rise of virtual clinics, and a broader cultural shift toward evidence-based medicine has triggered an "organic demand surge" for hormone therapy.

Central to this growth was a pivotal regulatory move: last fall, the U.S. Food and Drug Administration removed "black box" warnings from hormone therapy. During the announcement, Health and Human Services Secretary Robert F. Kennedy Jr. stated the move was part of challenging "outdated thinking." Alicia Jackson, the director of the Advanced Research Projects Agency for Health and founder of the telehealth company Evernow, noted the potential to add "up to a decade of healthy years" to women's lives.

This regulatory shift, paired with the post-pandemic normalization of telehealth and compounded products, has created a massive opportunity for specialized startups. An analysis conducted by SimilarWeb for Wired revealed that four primary players in the space—Midi, Winona, Alloy, and Evernow—experienced a 490 percent increase in web traffic between 2023 and 2026.

For operators, this trend highlights a move toward verticalized care. As demonstrated by the experience of Lisa Schrenk, who turned to Midi after being dismissed by primary care physicians and gynecologists, these platforms are capturing a demographic that feels underserved by traditional medical practitioners regarding the hormonal fluctuations of perimenopause.